Chemokine receptor binding heterocyclic compounds

A compound of the formula

• 135
• and the salts and prodrug forms thereof
• wherein
• the dotted lines represent optional unsaturation;
• R1 is a non-interfering substituent selected from halo, substituted or unsubstituted alkyl, substituted or unsubstituted hydroxyl, substituted or unsubstituted amino, substituted or unsubstituted thiol, and substituted or unsubstituted acyl;
• k is 0-3;
• each n is independently 0 or 1;
• each R is independently H or alkyl (1-6C);
• W is a 5-6 membered heterocyclic ring comprising one or more heterotoms, optionally fused with a benzene ring, or a benzene ring fused with another 5-6 membered heterocyclic ring, optionally containing a double bond;
• wherein W is optionally substituted with Yj;
• j is 0-3;
• each Y is independently a non-interfering substituent selected from the group consisting of halo, OR;
• SH;
• SO;
• SO2;
• optionally substituted phenyl;
• —(CR2)mOR;
• —(CR2)mCOR;
• —(CR2)mCOOR;
• —(CR2)mN═CH—NR2;
• —(CR2)mCN;
• —(CR2)mNR52;
• —(CR2)mNR(CR2)mNRR4;
• —(CR2)mNR(CR2)mNR(CR2)mNR52;
• —(CR2)mCO(CR2)mNR52;
• —(CR2)mCO(CR2)mNR(CR2)mNRR4;
• —(CR2)mCO(CR2)mNR(CR2)mNR(CR2)mNR52;
• —(CR2)mNRCO(CR2)mNRR4;
• —(CR2)mNRCO(CR2)mNR(CR2)mNR52;
• —(CR2)mNRCO(CR2)mNR(CR2)mNR(CR2)mNR(CR2)mNR52;
• —(CR2)mNROH;
• —(CR2)mCONROH;
• —(CR2)mCR═NOH;
• —(CR2)mguanidino;
• —(CR2)mCONHNHR;
• and
• —(CR2)mamidino;
• wherein R is H or alkyl (1-6C), each m is independently 0-4, and each R4 and each R5 is independently H, alkyl (1-6C), alkenyl (1-6C), alkynyl (1-6C), or acyl (1-6C), each optionally substituted by one or more nonaromatic, nonheterocyclic substituent(s) and a indicates the linker between Ring A and N and b indicates the linker between ring E and the N.